CLAIMS

1. A diagnostic agent for leukemia, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

2. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

3. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

4. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

5. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', $F(ab')_2$, a single chain antibody and a disulfide stabilized antibody.

6. The diagnostic agent according to claim 1, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

7. A therapeutic agent for leukemia, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

8. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

9. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

10. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

11. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab',

$F(ab')_2$, a single chain antibody and a disulfide stabilized antibody.

12. The therapeutic agent according to claim 7, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

13. A method for diagnosing leukemia, comprising using an anti-human VEGF receptor Flt-1 antibody.

14. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

15. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

16. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

17. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', $F(ab')_2$, a single chain antibody and a disulfide stabilized antibody.

18. The method for diagnosing leukemia according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

Sch A6 cont

add A7

EP0769560A2